Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin in Head and Neck Squamous Cell Carcinoma
NCT03510390Completed
- Sponsor
- Insel Gruppe
- Start
- Jun 2018
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of liquid metformin (Aspargo Labs) in oral cavity squamous cell carcinoma (OCSCC), sponsored by Insel Gruppe. Primary endpoint: Metformin dependent changes in gene expression at 2 weeks. Started Jun 2018; status: completed.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
oral cavity squamous cell carcinoma (OCSCC)
Beyond the preview
Go deeper on NCT03510390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03510390.